Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25436267 | 0.87 | ALDH1A1 (0.35) | CES2CES1ARBRPF1TNF | |
| SCHEMBL25748962 | 0.86 | TNF (0.33) | CES2CES1ARBRPF1TNF | |
| SCHEMBL29206559 | 0.80 | SMN1; SMN2 (0.34) | ARSMN1; SMN2 | |
| SCHEMBL25423230 | 0.80 | CES2 (0.39) | CES2CES1ARBRPF1TNF | |
| SCHEMBL4393222 | 0.79 | HTR1A (0.40) | CES2CES1MAPK14BRPF1TNF | |
| SCHEMBL29206360 | 0.78 | ALDH1A1 (0.40) | ARBRPF1TNFALDH1A1LMNA | |
| SCHEMBL25748906 | 0.77 | ALDH1A1 (0.49) | CES2CES1MAPK14ARALDH1A1 | |
| SCHEMBL31077708 | 0.77 | ALDH1A1 (0.49) | CES2CES1MAPK14ARALDH1A1 | |
| SCHEMBL31077764 | 0.73 | MAPK14 (0.45) | MAPK14 | |
| SCHEMBL25748812 | 0.73 | MAPK14 (0.45) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-03-27 | — | — | US | disclosed |
| CN-118715204-A | Compounds of formula (I) | 普赛洛私人有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | NLN, SLC18A2, PYGB | CES2 27/4885CES1 1556/4885MAPK14 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.